Trademark: AV AFFINIVAX 2181908
Word
AV AFFINIVAX
Device Descrption:
2 CHEVRONS,1 INVERTERD ARE LTRS
ID
2181908
Trademark Type
Figurative
Status
Protected: Registered/protected
Application Date
23 February 2021
Registration Date
23 February 2021
Renewal Date
23 February 2031
Owner(s)
Service
Goods and Services:
Class 5:
Vaccines; vaccines for the prophylaxis and treatment of infectious diseases and cancer; vaccines, namely, pharmaceutical preparations for use in immunotherapies for the treatment of infectious diseases and cancer; vaccines comprising polysaccharide antigens and protein-based antigens; vaccines, namely, pharmaceutical preparations for use in immunotherapies comprising polysaccharide antigens and protein-based antigens.
Vaccines; vaccines for the prophylaxis and treatment of infectious diseases and cancer; vaccines, namely, pharmaceutical preparations for use in immunotherapies for the treatment of infectious diseases and cancer; vaccines comprising polysaccharide antigens and protein-based antigens; vaccines, namely, pharmaceutical preparations for use in immunotherapies comprising polysaccharide antigens and protein-based antigens.
Class 42:
Research and development services in the field of vaccines; research and development services in the field of vaccines for the prophylaxis and treatment of infectious diseases and cancer; research and development services in the field of vaccines, namely, pharmaceutical preparations for use in immunotherapies for the treatment of infectious diseases and cancer; research and development in the field of vaccines comprising polysaccharide antigens and protein-based antigens; research and development in the field of vaccines, namely, pharmaceutical preparations for use in immunotherapies comprising polysaccharide antigens and protein-based antigens.
Research and development services in the field of vaccines; research and development services in the field of vaccines for the prophylaxis and treatment of infectious diseases and cancer; research and development services in the field of vaccines, namely, pharmaceutical preparations for use in immunotherapies for the treatment of infectious diseases and cancer; research and development in the field of vaccines comprising polysaccharide antigens and protein-based antigens; research and development in the field of vaccines, namely, pharmaceutical preparations for use in immunotherapies comprising polysaccharide antigens and protein-based antigens.